Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

George Sledge, MD, shares the most relevant findings from the MONARCH-2 trial

Dr. Sledge, Professor and Chief, Division of Oncology, Stanford Cancer Center, Stanford University School of Medicine, shares the most relevant findings from the MONARCH-2 trial investigating abemaciclib plus fulvestrant in women with metastatic hormone receptor-positive, HER2-negative breast cancer

Tags: BreastESMO 2019

Published: 10 October 2019

Recent Videos

video

Lori Leslie, MD, on real-world evidence regarding CAR-T cell therapy in lymphoma

Dr. Leslie, MD, Medical Oncologist, Regional Cancer Care Associates, offers her thoughts on the real-world evidence presented at ASH 2019 ...

video

Lori Leslie, MD, offers perspective on the role of umbralisib in relapsed/refractory lymphoma

Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, offers perspective on the role of umbralisib in the management of relapsed/refractory ...

video

John Mascarenhas, MD, on JAK inhibitors & combination therapies in myeloproliferative neoplasms

Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, elaborates on ...

video

Lori Leslie, MD, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma

Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma

video

John Mascarenhas, MD, on the role of molecular analysis in myeloproliferative neoplasms

Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, on whether ...

video

Lori Leslie, MD, considers how physicians should be thinking about the use of BTK inhibitors in CLL

Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, considers how physicians should be thinking about the use of BTK inhibitors ...

video

John Mascarenhas, MD, on the individualized management of myeloproliferative neoplasms

Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, tells us ...

video

Lori Leslie, MD, offers her perspective on the latest treatment trends in aggressive lymphomas

Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, offers her perspective on the latest treatment trends in Burkitt lymphoma and ...

video

Joshua Richter, MD, on the Phase 3 ICARIA-MM study from the 61st ASH Annual Meeting and Exposition

Dr. Richter, Assistant Professor, Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mt. Sinai School of Medicine, considers ...

video

John Mascarenhas, MD, shares outcomes from the MANIFEST study examining CPI-0610 in myelofibrosis

Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, shares outcomes ...

Related Videos

video-image

Catherine Smith, MD, discusses prognostic factors and outcomes in acute myeloid leukemia

video-image

Joshua Richter, MD, on the Phase 3 ICARIA-MM study from the 61st ASH Annual Meeting and Exposition

video-image

Leslie Popplewell, MD, summarizes the role of checkpoint inhibitors in the treatment of lymphomas

video-image

Lori Leslie, MD, offers her perspective on the latest treatment trends in aggressive lymphomas

video-image

Deepu Madduri, MD, explains how JNJ-4528 differs from other CAR-T products

video-image

John Mascarenhas, MD, on the individualized management of myeloproliferative neoplasms

video-image

Parameswaran Hari, MD, MRCP, tells us about the design & outcomes of the STORM and Mammoth studies

video-image

Lori Leslie, MD, considers how physicians should be thinking about the use of BTK inhibitors in CLL

video-image

Parameswaran Hari, MD, MRCP, considers the role of stem cell transplantation in myeloma

video-image

John Mascarenhas, MD, on the role of molecular analysis in myeloproliferative neoplasms

video-image

Parameswaran Hari, MD, MRCP, on novel combination treatment options & sequencing strategies in MM

video-image

Lori Leslie, MD, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma

video-image

Joshua Richter, MD, regarding the Phase 3 CANDOR study in relapsed/refractory multiple myeloma

video-image

John Mascarenhas, MD, on JAK inhibitors & combination therapies in myeloproliferative neoplasms

video-image

Parameswaran Hari, MD, MRCP, offers his impression of the Phase 3 ICARIA-MM trial from ASH 2019

video-image

Lori Leslie, MD, offers perspective on the role of umbralisib in relapsed/refractory lymphoma

video-image

Joshua Richter, MD, provides opinion on the role of BCMA CAR-T cells in the management of MM

video-image

Lori Leslie, MD, on real-world evidence regarding CAR-T cell therapy in lymphoma

video-image

Catherine Smith, MD, offers her overall impression on the changing FLT3 inhibition landscape in AML

video-image

Joshua Richter, MD, discusses the data investigating iberdomide presented at ASH 2019